Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 15/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.39 |
| ▸ | FAP | Q12884 | 5/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788517 | 0.82 | DPP4 (0.43) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL5789129 | 0.80 | DPP4 (0.44) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL5787459 | 0.80 | ALOX15 (0.39) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL5790525 | 0.79 | DPP4 (0.41) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL5791858 | 0.79 | DPP4 (0.40) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL5790640 | 0.75 | DPP4 (0.40) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL6165300 | 0.73 | DPP7 (0.39) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL6492871 | 0.73 | DPP7 (0.39) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL7418737 | 0.73 | DPP7 (0.39) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL5790030 | 0.71 | DPP4 (0.70) | DPP4DPP8DPP7DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622870-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | Prosidion Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004099134-A2 | GLUTAMINYL BASED DP IV-INHIBITORS | PROSIDION LTD. (GB) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | PROSIDION LIMITED (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229848-A1 | Glutaminyl based DP IV-inhibitors | DPP4, DPP3, DNPEP | DPP4 1/4885DPP8 7/4885DPP7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.